Ewing's sarcoma: standard and experimental treatment options

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ewing sarcoma family tumors (EWS) are the second most common primary bone cancer in adolescents and young adults.
• Current multi-disciplinary care improves localized EWS survival to nearly 70%, but metastatic/recurrent disease survival remains below 25% despite decades of chemotherapy optimization.
• A therapeutic plateau for advanced EWS persists despite efforts to enhance cytotoxic chemotherapy efficacy.

Purpose of the Study:

• To review the current standard-of-care for EWS patients.
• To highlight promising experimental therapies in early-phase clinical trials for EWS.
• To discuss the impact of the -omics revolution on understanding EWS and identifying therapeutic targets.

Main Methods:

• Review of current literature on EWS diagnosis, treatment, and emerging therapies.
• Analysis of advancements in molecular understanding of EWS formation.
• Identification of potential therapeutic targets and predictive biomarkers.

Main Results:

• Despite advances, survival for metastatic or recurrent EWS remains poor.
• -Omics-based research has identified potential molecular targets like IGF-1R and mTOR for biological therapy.
• Development of predictive biomarkers is crucial for selecting patients for targeted therapies.

Conclusions:

• Significant progress in EWS treatment has been made for localized disease, but advanced stages require novel therapeutic strategies.
• Molecularly targeted therapies and predictive biomarkers represent the future direction for improving outcomes in EWS.
• Early-phase clinical trials are exploring promising new treatment avenues for EWS.